Search results
Anne E. Wojcicki (/ wuːˈtʃɪtski / woo-CHITS-kee; [2] born July 28, 1973) is an American entrepreneur who co-founded and is CEO of the personal genomics company 23andMe. She founded the company in 2006 with Linda Avey and Paul Cusenza. She is a co-founder and board member of the Breakthrough Prize.
Sep 18, 2024 · Recent News. Anne Wojcicki (born July 28, 1973, San Mateo county, California) is an American entrepreneur and cofounder and chief executive officer of the personal genetics company 23andMe. Wojcicki received a B.S. degree (1996) in biology from Yale University. She later worked as a researcher and as an investment analyst.
Jun 1, 2023 · Anne Wojcicki is the cofounder and CEO of 23andMe, a pioneering direct-to-consumer genetics testing firm based in South San Francisco, California. In June 2021, 23andMe went public in a SPAC ...
2 days ago · Founder Anne Wojcicki races to rescue 23andMe on whatsapp (opens in a new window) Save. Stephanie Stacey and Ian Johnston in London and George Hammond in San Francisco. October 15 2024.
Oct 5, 2024 · Last month, the seven independent directors of the board sent an open letter to Anne Wojcicki, the chief executive and co-founder of 23andMe, notifying her of their resignation while citing ...
Sep 19, 2024 · The resignations follow drawn-out negotiations with 23andMe CEO and co-founder Anne Wojcicki, who wants to take the company private. In a Tuesday letter addressed to Wojcicki, the seven directors said they had yet to receive a “a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders” from the chief executive after months of ...
People also ask
Who is Anne Wojcicki?
Who started 23andMe?
Are Sergey Brin & 23andMe co-founder Anne Wojcicki divorced?
Who is Janet Wojcicki?
Why did 23andMe directors resign?
Does 23andMe make a profit?
Anne Wojcicki. CEO and Co-Founder. Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in ...